Wednesday, November 30, 2016

BRIEF-Helix Biopharma Corp accelerates escalation of l-dos47 dosing in the U.S. early-stage study

* Helix Biopharma Corp accelerates escalation of l-dos47

dosing in the U.S. Phase I study

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)